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Abstract
Background: Accumulation of extracellular matrix in organs and tissues is a feature of both 
ageing and disease. In the kidney, glomerulosclerosis and tubulointerstitial fibrosis 
accompany the decline in organ function, which is irretrievable with current therapies leading 
to inevitable kidney failure. Whilst histological and ultrastructural patterns of excess matrix 
form the basis of human disease classifications, the comprehensive molecular resolution of 
abnormal matrix is lacking. Methods: Using mass spectrometry-based proteomics we 
resolved matrix composition over age in mouse models of kidney disease. We compared the 
changes in mice with a global characterization of human kidney matrix during ageing and to 
existing kidney disease datasets to identify common molecular features. Results: We found 
that ultrastructural changes in basement membranes are associated with altered cell adhesion 
and metabolic processes and with distinct matrix proteomes during ageing and kidney disease 
progression in mice. Within the altered matrix, we observed a reduction in basement 
membrane components (laminins, type IV collagen, type XVIII collagen) and a corresponding 
increase in interstitial matrix proteins (collagens I, III, VI, XV, fibrinogens and nephronectin) 
and this pattern was also seen in human kidney ageing. Indeed, this signature of matrix 
proteins was consistently modulated across all age and disease comparisons and the increase 
in interstitial matrix was also observed in human kidney disease datasets. Conclusions: This 
study provides deep molecular resolution of matrix accumulation in kidney ageing and disease 
and identifies a common signature of proteins that provides insight into mechanisms of 
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Introduction
Extracellular matrix (ECM) is organized as basement membranes, which support continuous 
layers of cells, or as looser interstitial matrix (1). In addition to providing a scaffold ECM directs 
organ shape and sequesters growth factors and enzymes for controlled outside-in signalling 
(2). This extracellular environment is complex and dynamic with over 1000 matrisome proteins 
annotated (3). Matrix synthesis and turnover requires tight regulation for the maintenance of 
organ function, and matrix accumulation is associated with a wide spectrum of human disease. 
45% of deaths in the Western world have been associated with organ fibrosis (4). Thus, 
understanding the drivers of matrix accumulation is key to identifying strategies to prolong 
organ survival.
Excess matrix is seen across a wide spectrum of pathology and is incorporated into the 
histological and ultrastructural descriptions of many diseases (5). In the kidney, 
glomerulosclerosis is feature of ageing and glomerular disease (6) and tubulointerstitial 
fibrosis is seen with both primary tubular disease and as a consequence of glomerular disease 
(7, 8), yet the comprehensive molecular definition of altered matrix is limited. The use of 
proteomics to define global protein composition has improved the resolution of matrix 
complexity and this includes the human glomerular matrisome, which contains over 140 
structural and regulatory components (9, 10). Proteomic studies in kidney disease have also 
revealed changes in matrix composition (11, 12) but these have been limited by sample 
volume and have not utilized matrix enrichment strategies, which improve resolution (13).
Along the nephron there is distinct matrix composition within basement membranes and 
interstitial matrices (14). Basement membranes underly parietal epithelial cells, separate 
endothelial cells from overlying podocytes, provide a scaffold for tubular epithelial cells and 
form an integral component of blood vessel walls in the kidney. Interstitial matrices include the 
mesangial matrix and the loose tubulointerstitial matrix. The glomerular and tubular segments 
of the nephron have distinct functions and their differential matrix composition is likely to reflect 
their underlying functions including filtration and reabsorption. One example of structure 
supporting function is the triple helix of type IV collagen protomers, which may resist 
mechanical load (15) and could explain the distinct localisation of collagen IV isoforms along 
the nephron.
Here we performed deep proteomic profiling to define global changes in kidney matrix and to 
identify common components and pathways. In mouse models of genetic defects in collagen 
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metabolic processes and a signature of abnormal matrix composition. In young and aged 
human kidneys and existing kidney disease datasets we identified a similar signature of 
altered matrix. Broadly we observed a reduction in basement membrane components and an 
increase in interstitial matrix proteins in both mouse models and human tissue.
Methods
Antibodies: Primary antibodies were diluted in a blocking buffer (1% donkey serum, 2% BSA, 
0.1% Triton-X 100 in PBS). Primary antibodies used were against type VI collagen (ab6588, 
abcam) at 1/100 dilution and 1/500 dilution for STORM imaging, type IV collagen chains: α1, 
α2, α3, α4, α5 and α6 (7070, 7071, 7076, 7073, 7077, and 7074, respectively, Chondrex, 
Washington, USA) at 1/200 dilution, type I collagen (OARAO2579, Gentaur, Kapenhout, 
Belgium) at 1/100 dilution, podocin ab50339 (Abcam) at 1/400 dilution, fibulin-1 (sc-25281; 
Santa Cruz Biotechnology, Dallas, USA) at 1/100 dilution, nidogen/entactin antibody 
(MAB1946, ELM1, Merck, Germany) at 1/100 dilution, laminin beta 2 (ab210956, abcam) at 
1/100 dilution, Tinag (ab67614, abcam) at 1/100 dilution, integrin beta1 (BD Pharmigen, clone 
9EG7) at 1/500. Secondary antibodies conjugated to Alexa Fluor 488 or 594 (Life 
Technologies) were used for immunofluorescence.
Mice: We used Col4a1+/SVC mice, which carry a point mutation causing an amino acid 
substitution (G1064D) (16). These mice were on a BL6/C57 background, we used littermate 
controls, male mice for phenotypic consistency and n=3 mice from each group for proteomic 
analysis. Col4a3-/- mice were generated as described (17). In brief, the first three exons of the 
COOH-terminal (NC1) domain of collagen-α3(IV) chain were deleted, causing absence of 
collagen-α3(IV) protein. Col4a5-/- mice were obtained from the International Mouse 
Phenotyping Consortium (18). The line was generated by deletion of the critical exon 36 
resulting in the absence of the collagen-α5(IV) protein with the published allele map (19).  
Col4a3-/- and Col4a5-/- mice were on a BL6/C57 background, we used littermate controls, male 
mice for phenotypic consistency and we used n=5 mice from each group for proteomic 
analysis. All experiments were performed in compliance with the ASPA regulations of the UK 
Home Office.
Glomerular isolation from mice Cortical tissue was dissected from frozen-thawed, kidney 
placed in a glass dish and cut into small pieces (≤1mm3) as previously (9). Tissue pieces were 
washed three times with PBS. Tissue pieces were transferred onto a 100 µm cell strainer 
(Falcon) and mechanically disintegrated. PBS was added and flow through was collected. The 
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caught on the 70 µm cell strainer. The cell strainer was inverted and caught glomeruli were 
washed off the sieve and collected in a container. 
Human kidney: Human kidneys (n=6) anatomically unsuitable for transplantation and with no 
recorded comorbidities, were collected under ethical approval [Regional Ethics Committee 
approval 05/Q0508/6 (University College London) and 06/Q1406/38 (Manchester)]. Samples 
were grouped into young (15, 29, 37 years) and aged (61, 67, 69 years) with n=3 per group. 
5 of the 6 kidneys were from male donors and the sex of the 67 year old kidney was not 
recorded. Kidney biopsy sections from a male patient presenting at age 14 years with chronic 
kidney disease stage 3 due to autosomal recessive (COL4A3) Alport syndrome, and control 
kidney tissue (non-affected tissue of tumor nephrectomy) were also used with ethical approval 
06/Q1406/38 (Manchester). 
Glomerular and tubulointerstitial isolation from human kidney: Cortical tissue (2g) was 
dissected from frozen-thawed kidney placed in a glass dish and cut into small pieces (≤1mm3) 
as previously (9). Graded sieves 250µm, 150µm and 106µm were assembled with the 250µm 
sieve at the top and placed on a collection container. Tissue pieces were transferred onto the 
largest sieve in 5ml ice-cold PBS (without calcium and magnesium). The plunger from a 10ml 
syringe was used to press the sample through the sieves. Fragments were washed through 
the sieves with 60-100ml of ice-cold PBS. Glomeruli were retained on 150µm and 106µm 
sieves and were collected by inverting the sieves and washing with 20ml ice-cold PBS. Cortical 
tubulointerstitial (TI) fragments were retrieved from the collection container. The glomeruli and 
TI samples were centrifuged at 3,000xg for 3 minutes at 4°C then washed 3 times by 
centrifugation and resuspension in 10ml ice-cold PBS. After the final wash, samples were 
resuspended in 5ml PBS and aliquoted into five 1ml aliquots. One aliquot from each sample 
was viewed under a light microscope to confirm the separation of glomeruli and TI tissue. One 
aliquot was frozen at -20°C for ECM enrichment and the remainder stored at - 80°C.
Matrix enrichment: Samples stored at -20°C were defrosted at room temperature, 
homogenized using a 21G needle and 2ml syringe and centrifuged at 14,000xg for 5 minutes 
at room temperature. Ice-cold buffer solution 1 (500μl; 10mM Tris, 150mM sodium chloride, 
25mM EDTA, 1% (v/v) Triton X-100, 25µg/ml leupeptin, 25µg/ml aprotinin, 0.5mM 4-(2-
Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF)) was added to the pellet and 
samples incubated on ice for 1 hour. Samples were centrifuged at 14,000xg for 10 minutes at 
4°C, the supernatant was collected and mixed with 125μl recovery buffer (15% (w/v) SDS, 




This sample was designated soluble fraction 1 (most of the cellular compartment) and stored 
at -80°C. The pellet was resuspended in 500μl ice-cold buffer solution 2 (20mM NH4OH, 0.5% 
(v/v) Triton X-100) and incubated on ice for 1 hour. Samples were centrifuged at 14,000 x g 
for 10 minutes at 4°C, the supernatant collected and designated soluble fraction 2. The pellet 
was resuspended in 500μl PBS with DNase I (25µg/ml) and incubated for 30 minutes at room 
temperature. Samples were centrifuged at 14,000xg for 10 minutes at 4°C, the supernatant 
collected as soluble fraction 3. The final pellet was resuspended in a sample buffer and 
incubated for 10 minutes at 95°C to generate the ECM-enriched fraction. 
Mass spectrometry data acquisition: Following SDS–PAGE, gel lanes were sliced and 
subjected to in-gel digestion with trypsin (20) with modifications (21). Peptide samples were 
analyzed by liquid chromatography (LC)-tandem MS using a nanoACQUITY 
UltraPerformance LC system (Waters) coupled online to an LTQ Velos mass spectrometer 
(Thermo Fisher Scientific) or using an UltiMate 3000 Rapid Separation LC system (Thermo 
Fisher Scientific) coupled online to an Orbitrap Elite mass spectrometer (Thermo Fisher 
Scientific). Peptides were concentrated and desalted on a Symmetry C18 preparative column 
(20 mm × 180 μm, 5-μm particle size; Waters) and separated on a bridged ethyl hybrid C18 
analytical column (250 mm × 75 μm, 1.7-μm particle size; Waters) using a 45-min linear 
gradient from 1% to 25% or 8%–33% (v/v) acetonitrile in 0.1% (v/v) formic acid at a flow rate 
of 200 nl min−1. Peptides were selected for fragmentation automatically by data-dependent 
analysis.
Mass spectrometry identifications: Tandem mass spectra were extracted using 
extract_msn (Thermo Fisher Scientific) executed in Mascot Daemon (version 2.5.1; Matrix 
Science). Peak list files were searched against a modified version of the Uniprot mouse 
database (April 2016 database selected for Mus musculus) for mouse datasets, or Uniprot 
human database (November 2015 database selected for Homo Sapiens) for human datasets. 
Carbamidomethylation of cysteine was set as a fixed modification; oxidation of methionine and 
hydroxylation of proline and lysine were allowed as variable modifications. Only tryptic 
peptides were considered, with up to one missed cleavage permitted. Monoisotopic precursor 
mass values were used, and only doubly and triply charged precursor ions were considered. 
Mass tolerances for precursor and fragment ions were 5 ppm and 0.5 Da, respectively.
Mass spectrometry quantification: Relative protein abundance was calculated using 
peptide intensity. Orbitrap MS data were entered into Progenesis LC-MS (Non Linear 
Dynamics Ltd) and automatically aligned. Spectra were extracted using extract_msn executed 
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in Mascot Daemon (version 2.5.1; Matrix Science) and imported back into Progenesis LC-MS 
to acquire intensity data. Alignment of chromatograms was carried out using the automatic 
alignment algorithm, followed by manual validation and adjustment of the aligned 
chromatograms. All features were used for peptide identifications. Progenesis LC-MS created 
the peak list file that was exported and searched in Mascot. Protein abundance was inferred 
using Hi-N with the three most abundant peptides being used (22). Peptide and protein data 
were then exported from Progenesis LC-MS as.csv files to be analysed in Excel (Microsoft). 
Proteins identified by 1 unique peptide and a Mascot score indicating a <5% false discovery 
rate, were considered to be part of the definition of the human tubulointerstitial matrisome. 
The data was further filtered to include only proteins present in 2 out of 3 tubulointerstitial 
samples in a specific age group. Proteins identified by 3 unique peptides and a Mascot score 
indicating <5% false discovery rate were considered for quantitative analysis. 
Protein abundance was inferred from normalized peptide intensities using the 3 most 
abundant unique Hi-N peptides setting in Progenesis. Protein grouping was employed to 
resolve conflicts. Group protein abundances were compared across samples using ANOVA 
with post-hoc Bonferroni. To enable Gene Ontology lists with sufficiently large numbers of 
proteins in all comparisons, proteins with p<0.1 and 1.4 fold increased or decreased 
abundance were taken forward for further analysis.
Protein interaction network analysis: Protein interaction network analysis was performed 
using Cytoscape (version 3.7.2). Matrisome proteins were selected from the Matrisome 
Project (3) and proteins identified in at least two biological replicates were mapped onto a 
merged human, mouse and rat interactome. This was built from the PICKLE 2.5 (released on 
November 15 2019) (based on IntAct release 227/2019-11-04, BioGRID release 3.5.178, DIP 
release 20170205 and HPRD release 9) database merged with a matrix protein specific 
interactome Protein Interaction Network Analysis platform Homo sapiens network (release 
date, December 10, 2012), Mus musculus network (release date, December 10, 2012) and 
the Rattus norvegicus network (release date, December 10, 2012), the ECM interactions 
database MatrixDB (release date, April 20, 2012), and a literature-curated database of 
integrin-based adhesion–associated proteins (23). For networks where enrichment/fold 
change is presented, Progenesis LC-MS normalized intensity data were used. Networks were 
manually grouped.
Data analysis: Functional enrichment analysis was performed using DAVID (version 6.7). 
Keywords with fold enrichment ≥ 1.5, Bonferroni-corrected p value < 0.05, EASE score 
(modified Fisher’s exact test) < 0.05 and at least two proteins per keyword were considered 
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significantly overrepresented. Enrichment maps were generated using all changed proteins 
detected, p<0.1-fold change at least >1.4. Enrichment maps were clustered using the 
clusterMaker app with MCL tuning, granularity parameter 2.5. Principal component analysis 
was performed using MATLAB (version R2019a; MathWorks). Hierarchically clustered heat 
maps were generated on the basis of uncentred Euclidean complete linkage clustering in 
MultiExperiment Viewer (version 4.8.1). For clustered heat maps where Z-score or fold change 
is presented, Progenesis LC-MS normalized intensity data were used.





























































Nephroseq analysis: Nephroseq v5 was used for analysis. Signature matrix proteins were 
searched for their fold change in gene expression in disease datasets compared to associated 
control samples. The following filters were applied: tissue type; glomeruli and analysis type; 
disease versus control analyses. Microarray data were extracted with the  p-value selection: 
all and fold change: all. The primary data is shown in S.Table 4. Figure 8E shows data which 
met the following criteria: p-value <0.05, FC = +/- 1.5, these are highlighted in orange in 
S.Table 4. Data is shown as box and whiskers plots displaying all data points. Values below
every plot indicates the number of datasets that a transcript was detected out of all analysed
datasets (21 datasets). Data from the following datasets were extracted: Berthier Lupus
Glom; analysis: Lupus Nephritis vs. Healthy Living Donor (24), Hodgin Diabetes Mouse
Glom, analyses; Diabetic Nephropathy vs. Non-Diabetic Kidney (mouse model db/db
C57BLKS), Diabetic Nephropathy vs. Non-Diabetic Kidney (Mouse Model DBA/2), Diabetic
Nephropathy vs. Non-Diabetic Kidney (Mouse Model eNOS-deficient C57BLKS db/db) (25),
Hodgin FSGS Glom, analyses; Collapsing Focal Segmental Glomerulosclerosis vs. Normal
Kidney, Focal Segmental Glomerulosclerosis Vs. Normal Kidney, Minimal Change Disease
vs. Normal Kidney (26), Ju CKD Glom, analyses; Arterial Hypertension vs. Healthy Living
Donor,  Diabetic Nephropathy vs. Healthy Living Donor, Focal Segmental Glomerulosclerosis
vs. Healthy Living Donor, IgA Nephropathy vs. Healthy Living Donor, Lupus Nephritis vs.
Healthy Living Donor, Minimal Change Disease vs. Healthy Living Donor, Membranous
Glomerulonephropathy vs. Healthy Living Donor, Tumor Nephrectomy vs. Healthy Living
Donor, Thin Basement Membrane Disease vs. Healthy Living Donor, Vasculitis vs. Healthy
Living Donor , Neusser Hypertension Glom, analysis; Nephrosclerosis vs. Tumor
Nephrectomy (27), Peterson Lupus Glom, analysis; Lupus Nephritis vs. Normal Kidney (28),
Reich IgAN Glom, analysis; IgA Nephropathy vs. Healthy Living Donor (29) Woroniecka
Diabetes Glom, analysis; Diabetic Nephropathy vs. Healthy Living Donor (30).
Electron microscopy: Samples were prepared as previously (31). Briefly, mouse kidneys 




paraformaldehyde and 0.1M HEPES pH7.4. Samples were stained in 1% osmium tetroxide, 
1.5% potassium ferrocyanide in 0.1M cacodylate buffer, followed by 1% thiocarbohydrazide. 
Samples were washed and stained further in 1% osmium tetroxide and incubated in 1% uranyl 
acetate overnight. Samples were incubated in lead aspartate pH5.5 for 1h at 60°C, dehydrated 
and finally embedded in TAAB 812 hard resin. Samples were mounted onto an aluminium 
cryo pin. Block surfaces were trimmed using a glass knife or diamond trimming tool. To create 
a conductive surface, a gold coating was applied to the specimen. The samples were analysed 
using a Quanta 250 FEG (FEI Company) + Gatan 3view system. The analysed Col4a1+/SVC 
received treatment with 4-Sodium phenyl butyric acid as described before which did not affect 
the kidney phenotype (32) Kidney samples for transmission electron microscopy were fixed 
as for serial block face-scanning electron microscopy. 70-80nm thick sections were prepared 
and examined using a FEI Tecnai 12G2 Biotwin transmission electron microscope. Foot 
process width, GBM thickness and Bowman’s capsule basement membrane thickness were 
measured using ImageJ (Version 2.0.0-rc-68/1.52e). Foot process width was measured at the 
basal side of podocytes from 10 different fields of view in the glomerulus. Measurements were 
taken from one glomerulus per mouse genotype. GBM thickness was measured radially from 
the endothelial side of the electron-dense GBM to the basal membrane of podocyte foot 
processes. Bowman’s capsule thickness was measured radially in different sections of the 
acquired serial block face-scanning electron microscopy stack from one glomerulus.
Light microscopy: Formaldehyde-fixed, paraffin-embedded kidney sections were used for 
immunofluorescence. Images were acquired using a Zeiss Axioimager.D2 upright microscope 
(Photometrics) through Micromanager software v1.4.23. Images of stained cryosections were 
acquired using a Zeiss AxioObserver Z1 wide-field microscope equipped with a 40x / EC Plan-
neofluar 1.3 Oil objective and an Axiocam MRm camera, controlled by Zeiss Axiovision 
software. Specific band pass filter sets for DAPI, FITC and Texas red were used to prevent 
bleed through from one channel to the next. Images were processed and analysed using 
ImageJ (Version 1.51j8 and version 2.0.0-rc-68/1.52e). Total positive antibody fluorescence 
was measured in glomeruli and the TI separately and normalized to the total background in 
the same area to generate corrected total fluorescence. Background was subtracted using a 
rolling ball algorithm in ImageJ in the shown immunofluorescent images in Figure 3 and 
Figure 8. 
Tissue preparation and staining for STORM imaging: Tissue was fixed and stained as 
described previously (33, 34). In brief, kidneys were fixed in 4% paraformaldehyde (PFA) in 
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PBS. Samples were washed in PBS incubated in a cryoprotectant solution of 2.3M sucrose 
plus 10% polyvinylpyrrolidone (PVP) in 0.1M piperazine-N, N’-bis (PIPES) at pH = 7.2 at 4°C 
overnight. Tissue pieces were mounted on a metal sectioning pin and frozen in liquid nitrogen. 
Frozen tissue was sectioned using an EM-FC6 ultracryomicrotome (Leica) and collected on 
carbon-coated coverslips. Sections were fixed in 4% PFA for 20 minutes, washed with PBS 
and PFA was quenched using 50mM glycine in PBS. For immunofluorescence, sections were 
blocked in 2% BSA in PBS overnight followed by another overnight incubation of primary 
antibodies diluted in 2% BSA in PBS. After washing, sections were incubated with secondary 
antibodies diluted in 2% BSA in PBS for 2 hours at room temperature. Secondary antibodies 
for Direct-STORM were purchased from Jackson ImmunoResearch Laboratories and custom 
conjugated to Andy Fluor-488, -Cy3 or Cy5 reporter dyes as described previously (34). 
Sections were washed again in PBS and postfixed in 3% PFA plus 0.05% glutaraldehyde in 
PBS. After a final washing series, samples were imaged by Nikon N-STORM according to the 
manufacturer’s instructions as described (34).
Histology: Paraffin embedded mouse tissue sections were stained using a Shandon Linistain 
GLX stainer (Thermo Fisher) for hematoxylin and eosin. Samples were mounted using 
Histokitt solution (Roth). For Picro Sirius Red staining, paraffin-embedded tissue sections 
were dewaxed using a Leica ST5010 autostainer. Tissue sections were stained by incubation 
of slides in picro-sirius red solution [(0.5g Sirius Red (Sigma) and 500ml of saturated aqueous 
solution of picric acid (Sigma)] for one hour. Slides were washed in acidified water. Slides 
were dehydrated and mounted using Histokitt solution (Roth). Images were collected on an 
Olympus BX63 upright microscope using a 60x / 1.42 PlanApo N objective and captured and 
white-balanced using a DP80 camera (Olympus) in colour/polarised light mode through 
CellSens Dimension v1.16 (Olympus). For TriPAS staining paraffin sections were dewaxed 
and placed into 1% periodic acid for 10 minutes, and washed with tap and distilled water. 
Nuclei were stained with Gills No.2 haematoxylin for 1.5 minutes and washed in tepid tap 
water. Sections were stained in 2% orange G dissolved in 100 ml of 5% phosphotungistic acid 
for 1 minute.  Sections were washed, dehydrated and coverslipped. For human and mouse 
sections, a specialist kidney pathologist performed percentage glomerulosclerosis analysis 
and percentage interstitial fibrosis and tubular atrophy (IFTA) scoring on the TriPAS-stained 
tissue sections.
Urinary albumin and creatinine analysis: Spot urine was collected at the same time of the 
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(E99-134, Bethyl Laboratories). Creatinine was measured using a creatinine ELISA assay 
according to Manufacturer’s instructions (KGE005, R&D systems). 
Data sharing information: The proteomics data were deposited in the ProteomeXchange 
Consortium (35) via the PRoteomics IDEntifications database (PRIDE) partner repository with 
the dataset identifier PXD022363 “Col4a1 mouse glomerular datasets”, PXD022392 “Col4a3 
mouse glomerular datasets”, PXD022227 “Col4a5 mouse glomerular extracellular matrix and 
cellular fraction”, PXD022219 “Human kidney proteomics, glomerular and tubular cellular and 
matrix fractions”.
Statistical analysis: Data presented as bar charts (mean±SEM) or box-and-whisker plots 
and were analyzed using GraphPad Prism (version 7, GraphPad Software, La Jolla, CA, USA). 
Data were analyzed by Shapiro-Wilk test for normality and analyzed by Kruskal-Wallis test or 
ANOVA with post-hoc Bonferroni correction or t-test as appropriate. Statistical significance 
was accepted at p <0.05. Principal component analysis was performed in MATLAB. 
Unsupervised hierarchical clustering was performed in T4MeV using a Euclidean distance-
based complete-linkage matrix.
Results
Structural and compositional change in matrix
Type IV collagen is an essential component of basement membranes (BM) in the kidney and 
exists as three networks comprised of α1.α1.α2(IV), α3.α4.α5(IV) and α5.α5.α6(IV) 
heterotrimers. We confirmed the glomerular localization of these three networks with 
α1.α1.α2(IV) in the mesangium, GBM and Bowman’s capsule; α3.α4.α5(IV) in the GBM; and 
α5.α5.α6(IV) in Bowman’s capsule (S.Figure 1). To understand the impact of glomerular 
disease on matrix we investigated three mouse models with defects in the different collagen 
IV heterotrimers. Firstly Col4a1+/SVC mice, which harbor a glycine to aspartic acid variant 
(G1064D) and have phenotypic overlap with human COL4A1 variants, including defects in 
Bowman’s capsule, kidney cysts and tubular dysfunction (32, 36). Secondly Col4a3-/- mice 
(autosomal recessive Alport syndrome), which have progressive glomerular disease 
associated with GBM defects (17), and thirdly a new Col4a5-/- model of X-linked Alport 
syndrome. We characterized the Col4a5-/- mice and demonstrated abnormal GBM thickness, 
podocyte effacement and progressive albuminuria (S.Figure 2). To investigate the impact of 
Col4a defects on matrix ultrastructure, we performed serial block-face scanning electron 
microscopy of young (6-8 weeks), adult (16-18 weeks) and aged (28 weeks) mice (Figure 1A-
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thickened in adult Col4a3-/- and Col4a5-/-mice. Podocyte foot process width was preserved in 
Col4a1+/svc mice but increased over age with Col4a3-/- and Col4a5-/- mice. Bowman’s capsule 
BM thickness was increased in adult Col4a3-/- mice compared to adult wild type and Col4a5-/- 
mice and markedly thickened in aged Col4a3-/- mice (S. Video 3). Adult Col4a1+/svc mice had 
normal thickness of Bowman’s capsule BM, but there was infiltration of parietal epithelial cells. 
Given these structural changes in the matrix, we analyzed matrix composition using mass 
spectrometry-based proteomics. To interrogate changes that precede, and also coincide with 
ultrastructural changes, we analyzed glomerular proteomes in young and adult mice. We 
isolated glomeruli and separated cellular and matrix fractions from n=3 (Col4a1+/svc), n=5 
(Col4a3-/-) and n=5 (Col4a5-/-) mice and their respective littermate controls as previously 
described (9). Proteins were taken forward if identified by 3 unique peptides with a Mascot 
score indicating a <5% false discovery rate. Gene Ontology (GO) enrichment analysis 
highlighted increases in cell matrix and cell adhesion ontologies and a reduction in 
mitochondrial and metabolic components in all three Col4a models compared to controls 
(Figure 1E). Equivalent analyses of individual Col4a datasets highlighted similar cellular 
pathways (S.Figure 3A) and principal component analysis (PCA) demonstrated model and 
age segregation (Figure 2A). Taken together these findings highlight both structural and 
compositional changes in matrix in models of glomerular disease.
Evolution of altered matrix in ageing and disease
To explore the altered glomerular matrix we focused on the matrix-enriched fractions where 
707 (Col4a1+/svc), 334 (Col4a3-/-) and 600 (Col4a5-/-) proteins were detected. Volcano plots 
revealed age and genotype specific changes in protein identifications (Figure 2B-E). In 
keeping with predictions based on genotype, collagen-α1(IV)  and collagen-α2(IV) were 
reduced in Col4a1+/svc glomeruli but moderately increased in both Col4a3-/- and Col4a5-/-  
glomeruli (Figure 2F and S.Figure 4A). In addition, both collagen α3.α4.α5(IV) and laminin 
521 were reduced in Col4a3-/- and Col4a5-/- in contrast to Col4a1+/svc glomeruli (Figure 2F and 
S.Figure 4A) and immunofluorescence confirmed reduced levels of collagen-α3(IV) and
collagen-α4(IV) in Col4a5-/- mice (S.Figure 4B). Although ultrastructure was preserved in
young Alport mice (Figure 1), we observed altered matrix composition (Figure 2B,D and
S.Figure 5A and 6A) with a broad reduction in BM components and an increase in interstitial
matrix. This pattern was exaggerated in the older mice (Figure 2C,E and S.Figure 5B and
6B). Although less pronounced there were also changes during ageing in wild type mice, with
reduced collagen IV and increased collagen VI (S.Figure 3B). We performed
immunofluorescence on Col4a5-/- kidney sections and also observed increased collagen VI,
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used stochastic optical reconstruction microscopy (STORM) to determine the localization of 
increased collagen VI. Control heterozygous Col4a3+/- mice have normal kidney function (37) 
and we detected regular integrin β1 fluorescence and no GBM collagen VI. However, in 
Col4a3-/- mice we detected collagen VI in expanded regions of GBM (Figure 3C). Overall we 
found altered matrix composition prior to overt ultrastructural changes and these changes 
increased in ageing and disease progression.
Increased cell-matrix adhesion in disease
To connect the altered matrix with cell-matrix adhesion, we used the consensus adhesome 
(38) to select integrin adhesion complex components from all three disease model datasets
(Figure 4). The consensus adhesome is centred around four dominant signalling hubs: ILK-
PINCH-kindlin; FAK-paxillin; talin-vinculin and α-actinin-zyxin-VASP. Examining proteins
detected in cellular and matrix fractions across these hubs, we found a global increase in
abundance of integrin adhesion components and their respective ligands. In particular we
found parallel increases in the collagen binding integrins (α1β1, α2β1) with collagen VI,
collagen I and collagen III in addition to the parallel increase in α8β1 and its ligand
nephronectin. The observed global increase in adhesion components may reflect greater
receptor-ligand interaction associated with podocyte effacement.
Altered glomerular matrix in human kidney ageing
Having observed altered matrix in ageing and disease in mice, we examined human tissue. 
Glomerulosclerosis, tubular atrophy and interstitial fibrosis are observed in human ageing (45). 
Therefore, we investigated changes in matrix over age using unused human donor kidneys. 
Sections of young (15, 29, 37 years) and older (61, 67, 69 years) human kidneys were 
assessed blindly by a kidney pathologist who reported occasional focal glomerular and 
interstitial damage consistent with age. From these kidneys, glomeruli were isolated, 
subjected to matrix fractionation and analyzed by mass spectrometry. PCA of matrisome 
proteins showed good separation by age (Figure 5A) and GO enrichment analysis of all 
detected proteins highlighted matrix and cell-matrix ontologies (S.Figure 7A). Volcano plots 
and hierarchical clustering highlighted glomerular matrix proteins changing with age (Figure 
5B,C). There was a skewed distribution with a greater number of  increased abundance 
proteins in aged samples, including collagen VI and TIMP3 (Figure 5B). Fewer proteins were 
enriched in younger glomeruli including filaggrin-2, ECM1 and agrin. Protein-protein network 
mapping highlighted a reduction in BM components, including laminins and collagen IV, and 
an increase in interstitial matrix proteins (Figure 5D). Overall these findings highlight altered 
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composition of matrix during human glomerular ageing with similarity to ageing and disease 
in mice.
Defining the human tubulointerstitial matrisome
Together with altered glomerular matrix in kidney ageing and disease, there are changes in 
the tubulointerstitium (8) Matrix in this kidney compartment has received far less research 
attention and so we first defined the human tubulointerstitial (TI) matrisome. We isolated TI 
matrix from n=6 human kidneys (as above) for analysis by mass spectrometry. We included 
proteins identified by 1 unique peptide and a Mascot score indicating a <5% false discovery 





























































rate and present in 2 out of 3 samples in each age group. We robustly identified 141 proteins 
(S.Table 2) (S.Figure 8A,B) and 90% of all the components were also found in the glomerular 
matrix from this study and our previous investigation (9) Comparison of human glomerular and 
TI matrix revealed distinct proteomes (S.Figure 8C). Collagen-α3.α4.α5(IV) was abundant in 
the glomerular matrix, but also detected in the tubulointerstitium, which we validated by 
immunofluorescence (S.Figure 9A). We screened the Human Protein Atlas (39) to confirm 
localization of 67 components in the tubulointerstitium and 80 in both glomerular and TI 
compartments (S.Figure 9B,C). Combining the glomerular and TI datasets allowed us to 
define the combined human kidney matrisome, dominated by proteoglycans, collagens and a 
wide variety of matrix regulators and secreted factors (S.Figure 10). Together these data 
highlight the complexity of the TI matrix and key compositional differences with the adjacent 
glomerular compartment.
Altered tubulointerstitial matrix in human kidney ageing
Having defined the human TI matrisome, we compared TI matrices from young (15, 29, 37 
years) and aged (61, 67, 69 years) human kidneys. GO enrichment map analysis of all proteins 
highlighted increased matrix and cell-matrix adhesion ontologies, and a reduction in 
mitochondrial components (Figure 6A). We found age associated increases in structural 
components collagen VI, fibulin-1, fibronectin and matrix regulators TIMP3 and ADAMTS5 
(Figure 6B). Indeed several fibulin isoforms were increased in our mouse and human datasets 
and immunofluorescence confirmed increased fibulin-1 in the tubulointerstitium (Figure 6C,D). 
Furthermore, a number of age related changes were found in both glomerular and TI matrix 
including fibulin-1, TIMP3 and collagen VI (Figure 7A,B). There were also compartment 
distinct changes with reduced BM components observed in glomerular ageing but not seen in 
the aged TI matrix suggesting that tubular BMs are less exposed to damage during ageing. 
Relating these molecular changes to histology, we observed that ageing was only 
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atrophy (IFTA) scores (Figure 7C,D), in keeping with our finding in the mouse disease models 
that altered matrix composition precedes overt or widespread structural changes.
A signature of altered kidney matrix in ageing and disease. 
Across our ageing and disease datasets we observed consistent increases in collagen VI, 
nephronectin and fibrinogens and decreased BM components (Figure 8A,B). To investigate 
the relevance in human disease, we examined kidney biopsy sections from a young male 
patient with autosomal recessive Alport syndrome. Compared to control kidney sections, we 
observed increased levels of collagen VI and decreased levels of laminin-β2 in the glomerulus 
(Figure 8C). To determine whether this signature applied to a wider spectrum of human kidney 
disease, we searched for the signature proteins in published proteomic datasets. In a study of 
IgA nephropathy (11) we found consistency with increases in collagen VI and fibrinogen chains 
and in diabetic kidney disease (DKD) (12) there was increased collagen VI and nephronectin 
(Figure 8D). Data from a biopsy study of human focal segmental glomerulosclerosis (FSGS) 
identified increased interstitial collagen XV and Tgm2 (40). We also observed reduced BM 
components in IgA nephropathy and FSGS but not in DKD (Figure 8D), which may reflect the 
overall matrix expansion seen in DKD. To provide insight into the pathways associated with 
the matrix signature proteins, we created a 1-hop interaction network by 
connecting upregulated signature proteins with their nearest neighbours identified in 
protein interaction databases (S.Figure 11). This highlighted biological processes 
associated with matrix and adhesion but also with immune systems processes. We also 
compared the matrix signature proteins to RNA levels using the Nephroseq database and 
across a variety of phenotypes we observed similar increases in the signature transcripts 
(Figure 8E, S.Table 3,4). Finally we combined all primary, processed data from this study 
to allow direct evaluation (S.Table 5).
Discussion:
In this study we aimed to define altered matrix at the molecular level in kidney ageing and 
disease. We found: 1) ultrastructural change in matrix coupled with altered composition in 
models of glomerular disease, 2) similar patterns of altered glomerular matrix in human ageing 
with a reduction in BM proteins and an increase in interstitial matrix, 3) we defined the 
human tubulointerstitial matrix as a network of 141 components with a distinct pattern of 
altered matrix in ageing and 4) we observed a signature of altered matrix in kidney ageing 
and disease and provide evidence for shared pathobiology.
The processes that drive abnormal matrix in tissues remain unclear, although this 
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structure with evolution over age and disease progression. The GBM of Col4a3-/- and Col4a5/- 
mice at 6-8 weeks appeared normal, however proteomic analysis identified compositional 
change at this early stage. With age these disease models progressed with thickened GBM 
and the separation between control and disease matrix composition was more apparent. One 
aspect of the altered matrix was a reduction in BM components including collagen IV and 
laminins. In dynamic studies of endogenously tagged proteins in C. elegans, laminin and 
collagen IV orthologues have slower recovery after photobleaching compared to nidogens, 
agrin and perlecan (41). With this in mind, the reduction in BM components we observed could 
represent damage to these structures and an inability to replenish. We also observed 
increases in interstitial matrix with nephronectin and collagen VI, with integration of collagen 
VI into the GBM in Col4a3-/- mice. Genetic variants in COL6A1/2/3 cause Bethlem and Ulrich 
myopathies (42) but no reported kidney phenotype. However, collagen VI degradation has 
been associated with chronic kidney disease (43) and its cleavage product endotrophin 
triggers fibrosis and metabolic dysfunction (44). 
Glomerular capillaries are exposed to mechanical load during filtration. Loss of a key BM 
components may affect the mechanical properties of the GBM. Equally, loss of collagen VI 
has been shown to alter stiffness in the pericellular matrix of cartilage (45). Therefore collagen 
VI deposition in ageing and disease may occur to restore the mechanical properties of the 
GBM. Furthermore, collagen VI is a prominent downstream regulator of myofibroblast activity, 
with knockdown reducing fibrosis (46). Our data shows collagen VI increasing early where it 
may act to strengthen BM defects while paradoxically promoting fibrosis (Figure 8E). 
However, the role of increased collagen VI requires further investigation as does the potential 
for targeted inhibition. 
In parallel with altered matrix, we observed changes in cell adhesion components. The 
complex of proteins that assemble upon adhesion receptor and ligand engagement has been 
described for interactions with fibronectin (21) in addition to the BM ligands collagen IV and 
laminins (47). The consensus adhesome identified a series of four signalling hubs (38) and 
we found a global increase in components across all four signalling hubs. In addition, we found 
increases in receptors and their paired matrix ligand including integrin α1β1, integrin α2β1 with 
increased fibrillar collagens (I and III) and collagen VI and integrin α8β1 with nephronectin. 
Nephronectin is predominantly localized to the mesangium in the glomerulus and regulates 
mesangial cell adhesion (48), however increased GBM localization of nephronectin is reported 
in diabetic kidney disease (12). Our analysis of matrix receptors focussed on the integrin 
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This could be due to low abundance or due to factors limiting their detection by mass 
spectrometry. Overall, the changes we observed in adhesion components could be explained 
by increased cell-matrix adhesion associated with podocyte effacement and increased 
interaction with the GBM.
To relate our findings in mice to human tissue, we investigated matrix isolated from young and 
older human kidneys. We also found a reduction in BM components and increased collagen 
VI and nephronectin in the aged glomerular matrix. Indeed, these components were also 
increased in proteomic studies of IgA nephropathy (11), DKD (12) and collagen VI was also 
upregulated in aged human dentin (49). A Nephroseq analysis provided further correlation 
between matrix signature proteins and transcriptional change in a variety of glomerular 
phenotypes. Kidney disease and ageing is associated with altered tubulointerstitial matrix and 
we therefore defined the human tubulointerstitial matrisome. We confirmed localization of 70% 
of these proteins in different kidney matrix compartments using the Human Protein Atlas and 
thereby demonstrate the value of proteomics for increasing the known composition of matrix 
compartments as an adjunct to immunolocalization. We further examined the change in 
tubulointerstitial matrix in ageing and defined a profile of altered matrix. Interestingly we did 
not observe the same reduction in stable BM components seen in the glomerular matrix and 
hypothesize this is due to differential mechanical load on glomerular and tubular BMs (50), 
although this could also depend on the pathological process and a reduction of BM 
components was recently descripted in a proteomic analysis of transplant kidney rejection 
(51).
In addition to resident kidney cells secreting abnormal matrix, transiting or infiltrating immune 
cells may also contribute. Macrophage to fibroblast crosstalk has been shown to direct new 
matrix synthesis and the direct contribution of macrophages to collagen scar formation in the 
heart is described in zebrafish (52). Starting with the matrix signature proteins we identified 
experimentally confirmed protein interactors and demonstrated 3 clusters of enriched 
biological processes. Unsurprisingly, these included cell matrix and cell adhesion, but also 
processes related to complement, TNF, NFKb and immune response to infection. These 
findings suggest that the signature of an altered matrix has greater interaction with immune 
system components than previously recognized.
In conclusion we describe a molecular basis for altered matrix in the kidney with common 
features across ageing and disease. Further investigations will focus on the cellular origins of 
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Figure legends
Figure 1. Structural and compositional change in matrix. (a) Segmentation and modelling 
of serial block-face scanning electron microscopy data. Glomerular structure is visualized in 
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of Bowman’s capsule with enclosed nuclei. Col4a3-/- mice presented irregular GBM and 
progressive thickening of Bowman’s capsule, whilst Bowman’s capsule was conserved in the 
Col4a5-/- Alport mouse model. GBM (yellow), podocyte cell body with foot processes (light 
blue), Bowman’s capsule basement membrane (green) were reconstructed. Dark blue lines 
highlight the thickness of the Bowman’s capsule basement membrane. Nuclei of cells 
intercalate the basement membrane in Col4a1+/SVC are highlighted in pink. Note: The analysed 
Col4a1+/SVC received treatment with 4-Sodium phenyl butyric acid as described before which 
did not affect the kidney phenotype (38). (b) Quantification of GBM thickness; (c) podocyte 
foot process width (FPW); (d) Bowman’s capsule basement membrane (BCBM) thickness. 
Young mice were aged 6-8 weeks (Y), adult mice were 16-18 weeks (A) and aged mice were 
28 weeks old (A+). Box-and-whisker plots represent the median; box, interquartile range; 
whiskers, 10th to 90th percentile, n=1 biological sample per model. (e) Gene 
Ontology enrichment map analysis was performed on 719 proteins detected by mass 
spectrometry with altered abundance (>1.4 fold; p<0.1) in  Col4a1+/svc, Col4a3-/-, Col4a5-/- 
mice at all analyzed ages compared with aged-matched control mice. Overrepresented 
biological process terms are presented as nodes, colour represents Bonferroni-corrected p 
value, the lower the p value the more intense the node colour. Edge weight represents 
overlap between the proteins in the connected nodes, n=5 biological samples per mouse 
model studied. 
Figure 2. Evolution of altered matrix in ageing and disease. Mouse glomerular extracts 
were fractionated to cellular and matrix fractions. All fractions were analyzed by mass 
spectrometry, proteins were identified with Mascot and quantified using Progenesis. (a) 
Principal component analysis of all proteins detected was computed in Matlab. Components 
1 and 2 are presented and the percentage variance explained by component 1 is indicated 
on the x-axis and by component 2 on the y-axis. Samples were fractionated and the 
matrix fraction was further analyzed. (b-e) Volcano plots of proteins detected in matrix 
fractions demonstrate differential expression shown as log2(fold change) compared to aged, 
matched control on the x-axis and -log10(p-value) on the y-axis. (b) Col4a3-/- 6-8 weeks (c) 
Col4a3-/- 16-18 weeks (d) Col4a5-/- 6-8 weeks (e) Col4a5-/- 16-18 weeks. (f) Detected matrix 
proteins at the 6-8 weeks were clustered in MeV using Euclidean distance complete 
linkage. The clustered dendrogram is presented as a heatmap with orange 
representing increased abundance in Col4a mutant relative to control.
Figure 3: Altered matrix localization in Alport syndrome. Immunofluorescence 
demonstrated reduced BM proteins and increased interstitial matrix proteins in Alport mouse 
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for collagen 1, collagen VI, laminin-β2, Tinag and nidogen. Scale bar is 20 μm. (b) 
Quantification of (a). Mean fluorescence intensity was normalized to background and 
measured using ImageJ software. Images were acquired from n= 4 mice per genotype and 
between 10-15 glomeruli were analyzed per mouse, pooled data are shown. (c) Stochastic 
optical reconstruction microscopy was performed for integrin-β1 (green) and collagen VI 
(purple) on Col4a3+/- and Col4a3-/- mouse sections. Region of interest (ROI) highlights 
collagen VI localization to the GBM in Col4a3-/- glomeruli. Scale bar represents 2 micrometres.
Figure 4: Altered cell-matrix adhesion components. Unsupervised hierarchical clustered 
heatmap displaying the fold enrichment of adhesion proteins detected in 6-8 week Col4a1+/svc, 
Col4a3-/-, Col4a5-/- mass spectrometry datasets compared to their respective control, orange 
(+ is increased abundance in disease relative to control) blue (- represents decreased 
abundance in disease relative to control). Adhesion proteins are displayed along the four 
different signalling axes to the actin cytoskeleton as described previously (38).
Figure 5: Distinct matrix composition in human glomerular ageing. Glomeruli were 
isolated from young (15, 29, 37 years) and aged (61, 67, 69 years) human kidneys, subjected 
to matrix fractionation and analyzed by mass spectrometry. (a) Principal component analysis 
of matrisome proteins was carried out in Matlab, components 1 and 2 are presented and the 
percentage variance explained by each component is indicated on the relevant axis. (b) 
Volcano plots of proteins detected in matrix fractions demonstrate differential protein 
abundance shown as log2(fold change) glomerular aged over glomerular young on the x-axis 
and -log10(p-value) on the y-axis. (c) Unsupervised hierarchical clustered heatmap displaying 
extracellular matrix proteins detected in young and aged glomerular datasets. Data was 
standardised by row z-score and grouped in MeV using Pearson correlation complete linkage 
clustering. Inset line graph shows increased type VI collagen protein abundance with age. (d) 
Mass spectrometry data from matrix enriched protein fractions were filtered for known 
matrisome proteins. These proteins were mapped onto a merged human, mouse and rat 
interactome. Protein-protein interaction network of altered human glomerular matrisome 
proteins. Nodes represent proteins and edges represent reported protein-protein interactions. 
Colour represents fold enrichment to datasets, with increased abundance in aged human 
glomerular samples illustrated in red and increased abundance in young human glomerular 
samples illustrated in blue. Proteins are grouped by function. 
Figure 6: Molecular characterization of tubulointerstitial change in ageing. 
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human kidney samples. (a) Volcano plots of proteins detected in extracellular matrix fractions 
demonstrate differential protein abundance shown as log2(fold change) tubulointerstitial aged 
over tubulointerstitial young on the x-axis and -log10(p-value) on the y-axis.  (b) Unsupervised 
hierarchical clustered heatmap displaying extracellular matrix proteins detected in young and 
aged glomerular datasets. Data was standardised by row z-score and grouped in MeV using 
Pearson correlation complete linkage clustering. Inset line graph shows increased collagen VI 
protein abundance with age. (c) Mass spectrometry data from matrix enriched protein fractions 
were filtered for known matrisome proteins. These proteins were mapped onto a merged 
human, mouse and rat interactome. Protein-protein interaction network of altered human 
tubulointerstitial matrisome proteins. Nodes represent proteins and edges represent reported 
protein-protein interactions. Colour represents fold enrichment to datasets, with increased 
abundance in aged human tubulointerstitial samples illustrated in red and increased 
abundance in young human tubulointerstitial samples illustrated in blue. Proteins are grouped 
functionally. (d) Sections of normal human kidneys were stained with an antibody to fibulin-1 
(red) and nuclei were stained with Hoechst 33342 (blue). Representative images are shown. 
Magnification: left panel x40, right panel x20. (e) The fluorescent signal in 20 fields/kidney was 
quantified using ImageJ. ***: P value < 0.0005. ****: P value < 0.0001.
Figure 7: Comparison of the glomerular and tubulointerstitial matrix in ageing. (a) 
Unsupervised hierarchical clustered heatmap displaying extracellular matrix proteins detected 
in human glomerular and tubulointerstitial samples analysed by mass spectrometry. Data were 
standardized by row z-score, clustered using Pearson uncentered distance matrix and 
visualized in MeV. Comparison of human glomerular and human tubulointerstitial matrix 
proteins with age. Line graphs show laminin proteins with increased abundance in the human 
glomerular matrix relative to human tubulointerstitial samples. (b) Volcano plots of proteins 
detected in extracellular matrix fractions demonstrate differential protein abundance shown as 
log2(fold change) glomerular over tubulointerstitium on the x-axis and -log10(p-value) on the 
y-axis. (c) TriPAS staining of young and older kidney sections highlighting increased matrix in
the older kidney section. Scale bar represents 100μm. (d) Glomerulosclerosis and interstitial
fibrosis and tubular atrophy (IFTA) scoring in n=3 young and n=3 aged kidneys.
Figure 8: A signature of altered kidney matrix in ageing and disease. (a,b) Bar graph 
displaying protein fold change of consistently altered matrix signature proteins relative to their 
respective controls. Error bars represent standard deviation. #p<0.1, *p<0.05, **p<0.01, 
***p<0.001. (a) upregulated signature proteins. (b) downregulated signature proteins. (c) 




Video 1: SV1-Col4a1-16weeks. 
Video 2: SV2-Col4a3-16weeks. 
Video 3: SV3-Col4a3-28weeks. 
Video 4: SV4-Col4a5-16weeks. 
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Table S1: Abundance of matrix proteins in mouse models. 
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tissue (non-affected tissue of a tumor nephrectomy sample) were stained for type VI collagen, 
laminin beta 2 and nephrin. Scale bar is 50 μm (d) Dot plot comparison of signature matrix 
proteins to their protein levels in microdissected human IgA nephropathy samples (IgAN total 
and progressive IgAN) (11), human diabetic samples (12) and human FSGS samples 
(collapsing FSGS and FSGS not otherwise specified) (40) Significance (p<0.05) is indicated 
by an asterisk proximal to the datapoint. Fold change is presented on the y axis and dataset 
is highlighted by colour. (e) Analysis of signature protein transcript levels in different disease 
datasets using Nephroseq v5 database. Glomerular datasets were extracted and altered 
transcript levels with fold change +/- 1.5 and p<0.05 are shown. The % detection of searched 
gene transcript is shown (number of datasets = 21). Full details for Nephroseq datasets and 
transcript fold changes used for each signature gene can be found in S.Table 4. (f) Schematic 
of hypothesized basement membrane injury process.
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Abnormal extracellular matrix is a histological feature of kidney ageing and disease, however 
a comprehensive molecular basis for altered matrix is lacking. Combining ultrastructural and 
proteomic studies in mouse models of genetic kidney disease and human tissue, this study 
defines a molecular basis for altered matrix, which has common features across ageing and 
disease progression. Broadly there is a reduction of basement membrane components and 
an increase in interstitial matrix proteins coupled with altered cell adhesion and metabolic 
processes. Furthermore, a signature of altered matrix proteins appears prior to ultrastructural 
defects and could have utility as biomarkers of kidney health. Mechanistically, this altered 
kidney matrix may initiate abnormal kidney cell-matrix and immune cell-matrix interactions, 
which could be targeted by therapy.
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Supplemental Tables 
Table S1: Abundance of matrix proteins in mouse models. 
Table S2: Abundance of matrix proteins in human kidney.
Table S3: Human disease comparison.
Table S4:Nephroseq v5 analysis. 
Table S5: Normalized abundance for all primary datasets.
Figure S1: Glomerular localization type IV collagen isoforms. Wildtype mouse 
cryosections were stained for the different type IV collagen alpha chains (1-6) and the 
podocyte marker podocin. Col4a1 and Col4a2 localise to the glomerulus, specifically to the  
glomerular basement membrane and Bowman’s capsule basement membrane. Col4a3 and 
Col4a4 were detected in the GBM. Col4a5 was detected in the GBM and Bowman’s capsule. 
Col4a6 localized to Bowman’s capsule. Scale bar is 40 μm. 
Figure S2: Characterisation of Col4a5-/- mice. (a) Cryosections of Col4a5-/- and WT mice 
were immunolabeled for Col4a5 and the podocyte marker podocin. Scale bar is 40 μm. (b) 
Albumin and creatinine concentration was measured in urine from Col4a5-/- and WT mice and 
albumin-creatinine ratios were calculated. N=5 mice per group. (c) Paraffin sections from 
Col4a5-/- and wild type mice were prepared and H&E stained or (d) Picro Sirius Red staining 
was performed. Right panel shows Picro Sirius stains exposed to polarised light. White 
arrowhead highlights organised collagen fibers in Bowman's capsule. Scale bar is 40 μm. (e) 
Percentage glomerulosclerosis and interstitial fibrosis and tubular atrophy (IFTA) was scored 
by a kidney pathologist. Between 62 and 118 glomeruli were examined per mouse. Pooled 
data from n=3 wild type mice and n=4 Col4a5-/- mice are shown. (f) Kidney samples from 
Col4a5-/- and wild type mice were fixed and transmission electron microscopy (TEM) 
performed. Yellow arrowhead highlights an area of thickened basement membrane. (g) 
Quantification of (f). Number of foot processes per length of GBM was calculated. GBM 
thickness was measured from TEM images. Pooled data from n= 3 mice per group. 
Figure S3: Overview of glomerular proteomic data. (a)  Gene Ontology enrichment map 
analysis of all proteins detected by mass spectrometry with altered abundance (>1.4 fold; 
p<0.1) in Col4a1+/svc, Col4a3-/-, Col4a5-/- mice at all analysed ages compared with aged, 
matched control mice. Overrepresented biological process terms are presented as nodes. (b) 
Comparison of wild type mice at 6-8 weeks and 16-18 weeks of age. Mass spectrometry data 
from matrix enriched protein fractions were filtered for known matrisome proteins. These 
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protein interaction network of altered mouse matrisome proteins is shown. Nodes represent 
proteins and edges represent reported protein-protein interactions. Colour represents fold 
enrichment to datasets, with increased abundance in 16-18 week wild type mice in red and 
increased abundance in 6-8 week old wild type mice illustrated in blue. Proteins are grouped 
by function.
Figure S4: Altered matrisome proteins. (a) Selected profiles of matrix proteins detected 
with significantly altered protein abundance in Col4a1+/svc and young Col4a3-/- and Col4a5-/- 
mouse glomeruli by mass spectrometry. Data are presented as log10 fold change dot plots 
with the mean and standard deviation shown. (d) Immunofluorescence staining for Col4a1, 
Col4a2, Col4a3 and Col4a4 protein in both Col4a5-/- and WT mice. Scale bar is 70 μm.
Figure S5: Altered matrisome proteins in Col4a3-/- mice. (a,b) Mass spectrometry data 
from matrix enriched protein fractions were filtered for known matrisome proteins. These 
proteins were mapped onto a merged human, mouse and rat interactome. Nodes represent 
proteins and edges represent reported protein-protein interactions. Colour represents fold 
enrichment to datasets, with increased abundance in Col4a3-/- relative to control illustrated in 
red and decreased abundance in Col4a3-/- relative to control illustrated in blue. Proteins are 
grouped functionally. (a) Early time point, (b) late time point. 
Figure S6: Altered matrisome proteins in Col4a5-/- mice. (a,b) Mass spectrometry data 
from matrix enriched protein fractions were filtered for known matrisome proteins. These 
proteins were mapped onto a merged human, mouse and rat interactome. Nodes represent 
proteins and edges represent reported protein-protein interactions. Colour represents fold 
enrichment to datasets, with increased abundance in Col4a5-/- relative to control illustrated in 
red and decreased abundance in Col4a5-/- relative to control illustrated in blue. Proteins are 
grouped functionally. (a) Early time point, (b) late time point. 
Figure S7: Human kidney data enrichment analysis. (a) Gene Ontology enrichment map 
analysis of all proteins detected by mass spectrometry with altered abundance (>1.4 fold; 
p<0.1) in aged human glomerular samples compared with young human glomerular samples. 
Overrepresented biological process terms are presented as nodes, colour represents 
Bonferroni-corrected p value, the lower the p value the more intense the node colour. Orange 
represents terms increased with age and blue represents terms decreased with age. Edge 
weight represents overlap between the proteins in the connected nodes. (b)  Gene Ontology 
enrichment map analysis of all proteins detected by mass spectrometry with altered 
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tubulointerstitial samples. Overrepresented biological process terms are presented as nodes. 
Orange represents terms increased with age and blue represents terms decreased with age.
Figure S8: Defining the tubulointerstitial matrisome. Tubulointerstitial matrix was isolated 
from human kidney samples and subjected analyzed by mass spectrometry. (a) Mass 
spectrometry data from matrix enriched protein fractions were filtered for known matrisome 
proteins. These proteins were mapped onto a merged human, mouse and rat interactome. 
Protein-protein interaction network of human tubulointerstitial matrix proteins. (b) Principal 
component analysis of tubulointerstitial matrix mass spectrometry data. (c) Interaction network 
demonstrating enrichment of matrix proteins to either glomerular (green) or tubulointerstitial 
(orange) compartments. Dashed lines represent interactions, nodes represent proteins. Node 
size relates to connectivity within the network.
Figure S9: Identification of new tubulointerstitial matrix proteins. (a) 
Immunofluorescence of human kidney sections for Col4a1-6 (green). DAPI stain was used to 
highlight nuclei. Scale bar is 50 μm. (b) Percentage of TI matrix proteins identified in the 
Human Protein Atlas database and their localization to different kidney compartments. (c) 
Venn diagram classifying the identified TI matrix proteins into different groups according to 
their localisation to the tubulointerstitium, tubular basement membrane (TBM), glomerular 
matrix (mesangium, glomerular basement membrane and Bowman’s capsule basement 
membrane) and blood vessel matrix in the Human Protein Atlas database. 
Figure S10: Defining the human kidney extracellular matrix. Mass spectrometry data from 
matrix enriched protein fractions were filtered for known matrisome proteins. These proteins 
were mapped onto a merged human, mouse and rat interactome. Protein-protein interaction 
network shows combined tubulointerstitial and glomerular matrix fractions colour coded and 
grouped based on category of matrisome protein.
Figure S11: One-hop interactors of the upregulated matrix signature proteins. Gene 
ontology enrichment analysis was performed on the proteins that directly interact with the 
identified up regulated matrix signature proteins. Three clusters were identified and the 
enriched terms presented as bar charts with Benjamini significance presented on the x axis.
Supplemental Videos
Video 1: SV1-Col4a1-16weeks. Serial block face-scanning electron microscopy was 
performed on a Col4a1+/SVC mouse (16 weeks) kidney sample and 3 dimensional ultrastructure 
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shown in yellow, podocyte cell body in light blue, nuclei of parietal epithelial cells are shown 
in pink and bowman’s capsule basement membrane is shown in green. 
Video 2: SV2-Col4a3-16weeks. Serial block face-scanning electron microscopy was 
performed on a Col4a3-/- mouse (16 weeks) kidney sample and 3 dimensional ultrastructure 
of the glomerular filtration barrier was reconstructed using imod software. Glomerular BM is 
shown in yellow, podocyte cell body in light blue, bowman’s capsule basement membrane is 
shown in green, thickness of Bowman’s capsule is highlighted through dark blue lines. 
Video 3: SV3-Col4a3-28weeks. Serial block face-scanning electron microscopy was 
performed on a Col4a3-/- mouse (28 weeks) kidney sample and 3 dimensional ultrastructure 
of the glomerular filtration barrier was reconstructed using imod software. Glomerular BM is 
shown in yellow, podocyte cell body in light blue, bowman’s capsule basement membrane is 
shown in green and dark blue lines highlight thickened Bowman’s capsule.
Video 4: SV4-Col4a5-16weeks. Serial block face-scanning electron microscopy was 
performed on a Col4a5-/- mouse (16 weeks) kidney sample and 3 dimensional ultrastructure 
of the glomerular filtration barrier was reconstructed using imod software. Glomerular BM is 
shown in yellow, podocyte cell body in light blue, bowman’s capsule basement membrane is 
shown in green and the thickness of Bowman’s capsule is highlighted through dark blue lines.
Supplemental Tables 
Table S1. Abundance of matrix proteins identified and quantified using Progenesis were 
categorised as either basement membrane, other structural or ECM associated. A: Col4a1+/svc, 
B: Col4a3-/- (young and adult), C: Col4a5-/- (young and adult). Progenesis was used to 
quantify proteins with the Hi-N setting, the three most abundant peptides were used for protein 
quantification. Anova (p) was extracted from Progenesis.
Table S2. Abundance of matrix proteins identified and quantified using Progenesis were 
categorised as either basement membrane, other structural or ECM associated. A: human 
glomerular matrix (G) and B: human tubulointerstitial matrix (T) at a range of ages (15, 29, 37, 
61, 67 and 69 years).
Table S3. Signature matrix proteins were searched for their fold change gene expression 
levels of indicated disease datasets over control tissue samples. Data from the indicated 




Table S4. Nephroseq v5 database was used for analysis of transcript levels of identified down 
regulated signature proteins.
Table S5: Normalized abundance for all primary datasets.
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Identification of an altered matrix 
signature in kidney ageing and disease
Conclusion: We describe a molecular basis for altered matrix in the kidney with 
a reduction of basement membrane components and an increase in interstitial 
matrix across both ageing and disease suggesting shared pathobiology. 
We found: 1) ultrastructural change in matrix coupled with altered matrix and cell 
adhesion in models of glomerular disease, 2) similar patterns of altered glomerular 
matrix in human ageing with a reduction in basement membrane proteins and an 
increase in interstitial matrix, 3) we defined the human tubulointerstitial matrisome 
and identified a distinct pattern of altered matrix in ageing.
Global proteomics, ultrastructural analysis
& comparison to human disease datasets
Young & aged kidneys from mouse models & 
human nephrectomies
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